1126 completed, 340 terminated, 190 recruiting, 169 unknown. 975 Phase 2, 851 Phase 1, 183 Phase 3, 122 Not applicable, 21 Early Phase 1.
Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-08-26 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Tacabrutideg, Sonrotoclax, Obinutuzumab - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 30 | 2027-01-01 | 2026-10-21 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-10-26 |
| A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia Zanubrutinib, Obinutuzumab, Sonrotoclax - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 40 | 2026-12-31 | 2026-06-30 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 35 | 2026-12-19 | 2026-05-12 |
| Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated - Hematologic Malignancy, Acute Leukemia | Not applicable | Not yet recruiting | Ossium Health, Inc. | 300 | 2026-12-01 | 2026-09-10 |
| variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway Chronic Lymphocytic Leukemia, Haematological Malignancy | Not yet recruiting | The Royal Wolverhampton Hospitals NHS Trust | 130 | 2026-12-01 | 2026-09-15 | |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Zanubrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 95 | 2026-12-01 | 2026-09-14 |
| RPM Signals in Outpatient CAR T Therapy Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome | Not yet recruiting | Current Health | 125 | 2026-12-01 | 2026-10-20 | |
| A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLL Zanubrutinib, Sonrotoclax - CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | German CLL Study Group | 80 | 2026-12-01 | 2026-10-27 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Innovative 3D Preclinical Models for Mature B-cell Malignancies to Advance Personalized Immuno and Combination Therapies Chronic Lymphocytic Leukemia (CLL), Splenic Marginal Zone Lymphoma | Not yet recruiting | IRCCS San Raffaele | 64 | 2026-11-01 | 2026-08-13 | |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-01 | 2026-10-27 |
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-10-15 | 2026-09-11 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia) | Phase 2 | Not yet recruiting | University of California, Irvine | 24 | 2026-10-01 | 2026-09-14 |
Showing 20 of 2145. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (2019) · Lymphoma, Non-Hodgkin (772) · Lymphoma, Follicular (701) · Lymphoma, Mantle-Cell (674) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (652) · Lymphoma, B-Cell, Marginal Zone (631) · Lymphoma, Large B-Cell, Diffuse (598) · Lymphoma (541) · Leukemia (531) · Burkitt Lymphoma (474) · Hodgkin Disease (469) · Lymphoma, Large-Cell, Immunoblastic (418) · Leukemia, Myeloid, Acute (413) · Multiple Myeloma (403) · Waldenstrom Macroglobulinemia (349)
Hemic and Lymphatic Diseases (2145) · Neoplasms by Histologic Type (2140) · Immunoproliferative Disorders (2139) · Lymphatic Diseases (2136) · Immune System Diseases (2134) · Hematologic Diseases (2120) · Leukemia, Lymphoid (2114) · Lymphoproliferative Disorders (2098) · Pathological Conditions, Signs and Symptoms (2041) · Pathologic Processes (2040) · Disease Attributes (2037) · Chronic Disease (2025) · Neoplasms (2005) · Leukemia (1614)
Rituximab (321) · Cyclophosphamide (298) · fludarabine phosphate (217) · fludarabine (148) · ibrutinib (127) · Peripheral Blood Stem Cell Transplantation (116) · venetoclax (116) · Mycophenolic Acid (103) · obinutuzumab (99) · Bendamustine Hydrochloride (91) · Lenalidomide (91) · Whole-Body Irradiation (86) · Filgrastim (85) · Cyclosporine (78) · Tacrolimus (78)
National Cancer Institute (NCI) (138) · M.D. Anderson Cancer Center (117) · Fred Hutchinson Cancer Center (82) · Mayo Clinic (45) · Memorial Sloan Kettering Cancer Center (39) · City of Hope Medical Center (38) · Gilead Sciences (36) · Hoffmann-La Roche (36) · AbbVie (33) · German CLL Study Group (31) · National Heart, Lung, and Blood Institute (NHLBI) (31) · Masonic Cancer Center, University of Minnesota (30) · AstraZeneca (26) · Case Comprehensive Cancer Center (24) · Roswell Park Cancer Institute (23)
United States (1531) · France (176) · Italy (176) · United Kingdom (156) · Germany (154) · China (145) · Spain (136) · Canada (132) · Australia (119) · Poland (107) · Belgium (77) · Israel (74) · Austria (68) · Czechia (64) · South Korea (58)
Brenda Sandmaier (11) · Michael Hallek, MD (10) · Alessandra Ferrajoli, MD (8) · David Maloney (8) · Michael Choi, MD (8)
PMID 34515338, PMID 32499241, PMID 34398557, PMID 38620092, PMID 23524640, PMID 23065508, PMID 29358183, PMID 31196847, PMID 26182309, PMID 31023700, PMID 34608724, PMID 34865212, PMID 40266025, PMID 24615776, PMID 24615777, PMID 25103870, PMID 28751558, PMID 33131249, PMID 35829925, PMID 36442911, PMID 38502198, PMID 39563886, PMID 40396505, PMID 41843779, PMID 16344317, PMID 19238148, PMID 19826119, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 22133778, PMID 22289993, PMID 23547837, PMID 23886836, PMID 24055823, PMID 24443277, PMID 24450857, PMID 24450858, PMID 24615778, PMID 24782509, PMID 24797299, PMID 24916506, PMID 24990615, PMID 25317870, PMID 25381051, PMID 26472751, PMID 26813675, PMID 27482888
P30CA015704 (35), P30CA015083 (26), P30CA033572 (26), 2023 (18), P30CA043703 (16), U10CA031946 (16), 2015 (15), P30CA006973 (15), U01CA076576 (15), P30CA016672 (14), 2009 (12), 2025 (12), P01CA018029 (12), P30CA016058 (12), P30CA022453 (12)